News

Roche has reported that the Phase III REGN-COV 2067 trial of investigational antibody cocktail of casirivimab and imdevimab met its primary endpoint of reducing the risk of hospitalisation or death in treating high-risk, non-hospitalised Covid-19 patients, by 70%. Regeneron scientists...

Regeneron Pharmaceuticals, Inc. announced positive topline results from the largest trial to date assessing a COVID-19 treatment in infected non-hospitalized patients (n=4,567). This definitive Phase 3 outcomes trial in high-risk non-hospitalized COVID-19 patients ("outpatients") met its primary endpoint, showing...

BioAge Labs, Inc., a clinical-stage biotechnology company developing medications that target aging to treat severe diseases, announced that it has commenced a Phase 2 clinical trial of BGE-175, a potent oral inhibitor of prostaglandin D2(PGD2) DP1 signaling with a...

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, announced that it has entered into a master services agreement (MSA) with Piramal Pharma Solutions (PPS) for the development, manufacture, and...

ICPA Health Products Ltd (ICPA), India’s leading pharma company in the oral healthcare segment, as part of its CSR activity has donated a sum of Rs.21 lakhs to the PM CARES Fund towards the COVID19 pandemic relief. With India...

Glenmark Pharmaceuticals has received final approval by the United States FDA for diltiazem hydrochloride extended-release capsules USP, 60 mg, 90 mg, and 120 mg. This is the generic version of Cardizem SR extended-release capsules, 60 mg, 90 mg, and...

Eisai Co., Ltd. announced that, as part of one strategic investment towards the realization of its medium-term business plan “EWAY2025”, it has conducted the groundbreaking ceremony for the construction of a new injection/research building “Eisai Medicine Innovation Technology Solutions”...